A pilot study on tacrolimus treatment in membranous or quiescent lupus nephritis with proteinuria resistant to angiotensin inhibition or blockade

Lupus

Volumn 16, Issue 1, 2007, Pages 46-51

  Tse, K C ^a   Lam, M F ^a   Tang, S C W ^a   Tang, C S O ^a   Chan, T M ^a,b  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b QUEEN MARY HOSPITAL   (Hong Kong)

Author keywords

Calcineurine inhibitor; Membranous lupus nephritis; Proliferative lupus nephritis; Tacrolimus

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; AZATHIOPRINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; SERUM ALBUMIN; TACROLIMUS;

ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CREATININE CLEARANCE; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN TISSUE; HYPERGLYCEMIA; HYPERTENSION; HYPOALBUMINEMIA; INFECTION COMPLICATION; KIDNEY BIOPSY; LUPUS ERYTHEMATOSUS NEPHRITIS; MALE; NEPHROTOXICITY; PRIORITY JOURNAL; PROTEINURIA;

ADULT; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIBODIES, ANTINUCLEAR; AUTOANTIGENS; BLOOD GLUCOSE; BLOOD PRESSURE; COMPLEMENT C3; CREATININE; DNA; DRUG EVALUATION; DRUG RESISTANCE; FEMALE; HUMANS; HYPOALBUMINEMIA; IMMUNOSUPPRESSIVE AGENTS; KIDNEY DISEASES; LIPIDS; LUPUS NEPHRITIS; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PILOT PROJECTS; PREDNISOLONE; PROTEINURIA; RETROSPECTIVE STUDIES; SERUM ALBUMIN; TACROLIMUS; TREATMENT OUTCOME;

EID: 33846613753     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/0961203306073167     Document Type: Article

References (35)

1. Austin HA 3rd, Klippel JH, Balow JE et al. Therapy of lupus nephritis. Controlled trial of prednisolone and cytotoxic drugs. N Engl J Med 1986; 314: 614-619.
2. Boumpas DT, Austin HA, Vaughn EM et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse CYC in severe lupus nephritis. Lancet 1992; 340: 741-745.
3. Houssiau FA, Vasconcelos C, D'Cruz D et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomised trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 2002; 46: 2121-2131.
4. Chan TM, Li FK, Tang CSO et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. N Engl J Med 2000; 343: 1156-1162.
5. Chan TM, Tse KC, Tang CSO et al. for the Hong Kong Nephrology Study Group. Long-term study of mycofenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol 2005; 16: 1076-1084.
6. Chan TM, Tse KC, Tang CS, Lai KN, Li FK. Long-term outcome of patients with diffuse proliferative lupus nephritis treated with prednisolone and oral cyclophosphamide followed by azathioprine. Lupus 2005; 14: 265-272.
7. Bartosik LP, Lajoie G, Sugar L, Cattran DC. Predicting progression in IgA nephropathy. Am J Kidney Dis 2001; 38: 728-735.
8. Honkanen E, Tomroth T, Gronhagen-Riska, Sankila R. Long-term survival in diopathic membranous glomerulonephritis: can the course be clinically predicted? Clin Nephrol 1994; 41: 127-134.
9. Jose P, Tomsen C, Skali H et al. Influence of proteinuria on cardiovascular risk and response to angiotensin-converting enzyme inhibition after myocardial infarction. J Am Coll Cardiol 2006; 47: 1725-1727.
10. de Zeeun D, Remuzzi G, Parving HH et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 2004; 110: 921-927.
11. Gruppo Italiano Studi Epidemiologici in Nefrologia (GISEN). A long-term, randomised clinical trial to evaluate the effects of ramipril on the evolution of renal function in chronic nephropathies. J Nephrol 1991; 3: 193-202.
12. Ruggenenti P, Perna A, Gherardi G et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proetinuria. Lancet 1999; 354: 359-364.
13. Tse KC, Li FK, Tang S, Tang CS, Lai KN, Chan TM. Angiotensin inhibition or blockade for the treatment of patients with quiescent lupus nephritis and persistent proteinuria. Lupus 2005; 14: 947-952.
14. Ponticelli C, Zucchelli P, Imbaciati E et al. Controlled trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy. N Engl J Med 1984; 310: 946-950.
15. Ponticelli C, Zucchelli P, Passerini P et al. A randomised trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy. N Engl J Med 1989; 320: 8-13.
16. Cattran DC, Greenwood C, Ritchie S et al. A controlled trial of cyclosporine in patients with progressive membranous nephropathy. Canadian Glomerulonephritis Study Group. Kidney Int 1995; 47: 1130-1135.
17. Cattran DC, Appel GB, Hebert LA et al. North America Nephrotic Syndrome Study Group. Cyclosporine in patients with steroid-resistant membranous nephropathy: a randomized trial. Kidney Int 2001; 59: 1484-1490.
18. Szeto CC, Leung CB, Lai FM, Li PK. Tacrolimus in resistant primary membranous nephropathy-a report of 3 cases. Clin Nephrol 2003; 59: 293-296.
19. Chang T, Wu MS. Successful treatment of idiopathic membranous glomerulonephritis complicated with renal vein thrombosis with FK506. Ren Fail 2002; 24: 523-528.
20. Donadio JV Jr, Burgess JH, Holley KE. Membranous lupus nephropathy: a clinicopathologic study. Medicine (Baltimore) 1977; 56: 527-536.
21. Sloan RP, Schwartz MM, Korbet SM, Borok RZ. Long-term outcome in systemic lupus erythematosus membranous gloerulonephritis. Lupus Nephritis Collaborative Study Group. J Am Soc Nephrol 1996; 7: 299-305.
22. Korbet SM. Angiotensin antagonists and steroids in the treatment of focal segmental glomerulosclerosis. Semin Nephrol 2003; 23: 219-228.
23. Balow JE, Austin HA 3rd. Therapy of membranous nephropathy in systemic lupus erythematosus. Semin Nephrol 2003; 23: 386-391.
24. Tam LS, Li EK, Szeto CC et al. Treatment of membranous lupus nephritis with prednisolone, azathioprine and cyclosporin A. Lupus 2001; 10: 827-829.
25. Chan TM, Li FK, Hao WK et al. Treatment of membranous lupus nephritis with nephrotic syndrome by sequential immunosuppression. Lupus 1999; 8: 545-551.
26. Mok CC, Ying KY, Lau CS et al. Treatment of pure membranous lupus nephropathy with prednisone and azathioprine: an open-label trial. Am J Kidney Dis 2004; 43: 269-276.
27. Maruyama M, Yamasaki Y, Sada K et al. Good response of membranous lupus nephritis to tacrolimus. Clin Nephrol 2006; 65: 276-279.
28. Hu W, Liu Z, Shen S et al. Cyclosporine A in treatment of membranous lupus nephropathy. Chin Med J (Engl) 2003; 116: 1827-1830.
29. Hallegua D, Wallace DJ, Metzger AL, Rinaldi RZ, Klinenberg JR. Cyclosporine for lupus membranous nephritis: experience with ten patients and review of the literature. Lupus 2000; 9: 241-251.
30. Radhakrishnan J, Kunis CL, D'Agati V, Appel GB. Cyclosporine treatment of lupus membranous nephropathy. Clin Nephrol 1994; 42: 147-154.
31. Duddridge M, Powell RJ. Treatment of severe and difficult cases of systemic lupus erythematosus with tacrolimus. A report of three cases. Ann Rheum Dis 1997; 56: 690-692.
32. von Pelchrzim R, Schmook T, Friedrich M, Worm M. Efficacy of topical tacrolimus in the treatment of various cutaneous manifestations of lupus erythematosus. Int J Dermatol 2006; 45: 84-85.
33. Mok CC, Tong KH, To CH, Siu YP, Au TC. Tacrolimus for induction therapy of diffuse proliferative lupus nephritis: an open-labeled pilot study. Kidney Int 2005; 68: 813-817.
34. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR. The natural history of chronic allograft nephropathy. N Engl J Med 2003; 349: 2326-2333.
35. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Chapman JR, Allen RD. Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology. Transplantation 2004; 78: 557-565.